|Bid||1,607.40 x 0|
|Ask||1,607.80 x 0|
|Day's range||1,600.40 - 1,636.80|
|52-week range||1,328.19 - 1,857.00|
|Beta (5Y monthly)||0.42|
|PE ratio (TTM)||15.11|
|Earnings date||29 Jul 2020|
|Forward dividend & yield||0.76 (4.60%)|
|Ex-dividend date||14 May 2020|
|1y target est||1,644.50|
GlaxoSmithKline (NYSE: GSK) announced Tuesday that Medicago -- a private company owned by Mitsubishi Tanabe Pharma (OTC: MTZXF) and Philip Morris International (NYSE: PM) -- will use GlaxoSmithKline's adjuvant in a COVID-19 vaccine it expects to enter phase 1 trials this month. Medicago's recombinant coronavirus "Virus-Like Particles" will be combined with Glaxo's pandemic adjuvant system to boost immune response, potentially allowing for less antigen per dose and thus, more available vaccine doses.
GlaxoSmithKline's shares have underperformed this year and Anna Sokolidou thinks they're a bargain today. Here's why.The post Forget Cash ISAs. I'd buy this FTSE 100 company instead appeared first on The Motley Fool UK.
Britain is close to a 500 million pound ($624 million) supply deal with Sanofi and GlaxoSmithKline for 60 million doses of a potential COVID-19 vaccine, the Sunday Times reported. Clinical trials are due to start in September and Sanofi <SASY.PA> has said it expects to get approval by the first half of next year, sooner than previously anticipated. More than 100 vaccines are being developed and tested around the world to stop the COVID-19 pandemic and governments are racing to secure supplies of vaccines even before their efficacy is proven.
The GSK share price looks to have the potential to produce large total returns for long-term investors in the years ahead. The post I think the GSK share price could help you retire early appeared first on The Motley Fool UK.
These two UK shares have fallen in the stock market crash and could offer much better return prospects than gold or Bitcoin in my view.The post Forget gold and Bitcoin. I’d buy these 2 crashing UK shares today to make a million appeared first on The Motley Fool UK.
July may be a good time to start investing in relatively cheap FTSE 100 (INDEXFTSE: UKX) shares through a Stocks and Shares ISA.The post FTSE 100 shares are cheap! I believe investing in an ISA in July may help you retire rich appeared first on The Motley Fool UK.
GlaxoSmithKline's HIV business ViiV is within weeks of resubmitting its request for approval of its long-acting injection Cabenuva to U.S. drug regulators, ViiV's head of research said on Thursday. ViiV executive Kimberly Smith told a media briefing that the company would stick to its previous guidance of refiling the request around mid-year and that this would happen "within weeks".
Invest in GlaxoSmithKline now and you could benefit from a share price recovery, driven by increased sales, profits and a generous quarterly dividend. The post I think the GlaxoSmithKline share price could help you retire early appeared first on The Motley Fool UK.
We asked our freelance writers to share their top British stocks for July including Prudential, BAE Systems, and Crest Nicholson.The post Top British stocks for July 2020 appeared first on The Motley Fool UK.
GlaxoSmithKline (GSK) closed at $40.55 in the latest trading session, marking a -1.39% move from the prior day.
Shares in Glaxosmithkline (LON:GSK) are currently trading at 1633.8 but the question for investors is how much the market chaos of 2020 will impact on its pric...
Stocks are trading at rock-bottom prices right now. But investor tension means that many are resisting the urge to buy in. Here I look at two FTSE 100 stocks that are too cheap to miss.The post Don't know what stocks to buy? I’d buy cheap FTSE 100 shares in an ISA appeared first on The Motley Fool UK.
French drugmaker Sanofi SA said on Tuesday it expects to get approval for the potential COVID-19 vaccine it is developing with Britain's GlaxoSmithKline Plc by the first half of next year, faster than previously anticipated. Sanofi, which is hosting a virtual research and development event, and GSK had said in April the vaccine, if successful, would be available in the second half of 2021. "We are being guided by our dialogue with regulatory authorities," Sanofi research chief John Reed told reporters, when asked about the accelerated time frame.
Glaxo (GSK) has several collaborations to make its pandemic adjuvant technology available to partners who are making adjuvanted COVID-19 vaccine candidates.
If you're new to investing and want to profit from the stock market crash, these could be the best UK shares to buy now, says Roland Head.The post I think these are the best UK shares to buy for beginner investors appeared first on The Motley Fool UK.
There is a notable name missing from the frontrunners in the race to test experimental immunisations against the novel coronavirus: the world's largest vaccine maker GlaxoSmithKline <GSK.L>. The company laid out plans in May to produce 1 billion doses of the efficacy boosters for COVID-19 shots next year, compared to the 700 million or so vaccine doses against a range of diseases it usually produces in a year.
FDA approves Glaxo's (GSK) oral suspension formulation of its three-drug regimen for HIV, Tivicay, as a treatment for patients aged at least four weeks and weighing at least 3kg.
The FTSE 100 fell nearly 6% last week, its biggest fall in three months. Meanwhile, this top share combines a 5% yearly payout with future growth.The post Neil Woodford completely ditched this FTSE 100 stock, but I'd happily buy it today! appeared first on The Motley Fool UK.
AstraZeneca reached an agreement with Europe’s Inclusive Vaccines Alliance to supply up to 400 million doses of a COVID-19 vaccine.